跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis
C. H. Shih
, Y. J. Chang
, W. C. Huang
, T. H. Jang
, H. J. Kung
, W. C. Wang
,
M. H. Yang
, M. C. Lin
, S. F. Huang
, S. W. Chou
, E. Chang
, H. Chiu
, T. Y. Shieh
, Y. J. Chen
, L. H. Wang
, L. Chen
*
*
此作品的通信作者
國立陽明交通大學
臨床醫學研究所
研究成果
:
Article
›
同行評審
41
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Upregulation
100%
Metastatic Carcinoma
100%
Oral Cancer
100%
Oncogene
100%
Mouth Squamous Cell Carcinoma
75%
Epidermal Growth Factor Receptor
50%
Lung
50%
Neoplasm
25%
Downregulation
25%
Biological Marker
25%
Cancer
25%
Intravenous Drug Administration
25%
Xenograft
25%
Oral Cavity
25%
Histone H3
25%
Lysine
25%
Cell Proliferation
25%
Lymph Node
25%
Cancer Therapy
25%
Drug Resistance
25%
Intron
25%
Enhancer Region
25%
Tail Vein
25%
Squamous Cell Carcinoma Cell
25%
Histone Methyltransferase
25%
Anti-Epidermal Growth Factor Receptor
25%
Gene Rearrangement
25%
STAT1 Protein
25%
Keyphrases
Cancer Metastasis
100%
Enhancer of Zeste Homolog 2 (EZH2)
100%
Oral Cancer
100%
ROS1
100%
ROS1 Oncogene
100%
Epidermal Growth Factor Receptor
25%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
25%
Metastases to Lung
25%
Tumor
12%
Strong Correlation
12%
Mechanistic Studies
12%
Transcription Factor
12%
Novel Mechanism
12%
Oncogene
12%
Xenograft Model
12%
Oral Cavity
12%
Cell Proliferation
12%
Therapeutic Target
12%
Drug Resistance
12%
Oral Cancer Patients
12%
CXCL1
12%
Chromatin
12%
Anti-epidermal Growth Factor Receptor Therapy
12%
Lymph Node
12%
Co-target
12%
Tail Vein Injection
12%
Targets for Therapy
12%
Oral Squamous Cell Carcinoma Cells
12%
Gli1
12%
Trimethylation
12%
Histone H3 Lysine 27
12%
Carcinoma Metastasis
12%
Gene Rearrangement
12%
Oral Cancer Therapy
12%
Histone Methyltransferase EZH2
12%
Biochemistry, Genetics and Molecular Biology
Upregulation
100%
Oncogene
100%
EZH2
100%
ROS1
100%
Epidermal Growth Factor Receptor
33%
Downregulation
11%
Drug Resistance
11%
Enhancer Region
11%
Histone H3
11%
Cell Proliferation
11%
STAT1
11%
Intron
11%
CXCL1
11%
GLI1
11%
Histone Methyltransferase
11%
Gene Rearrangement
11%
Lysine
11%